Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo

Journal of Clinical Investigation

Volumn 113, Issue 1, 2004, Pages 38-48

  Ling, Qi ^a   Jacovina, Andrew T ^a   Deora, Arunkumar ^a   Febbraio, Maria ^a   Simantov, Ronit ^a   Silverstein, Roy L ^a   Hempstead, Barbara ^a   Mark, Willie H ^b   Hajjar, Katherine A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; COLLAGEN; COLLAGENASE 3; FIBRIN; FIBROBLAST GROWTH FACTOR; GELATINASE B; LIPOCORTIN 2; MATRIGEL; PEPTIDE; PLASMIN; PLASMINOGEN; REGULATOR PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; MATRIX METALLOPROTEINASE; VASCULOTROPIN A;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXPLANT; FEMALE; FIBRIN DEPOSITION; FIBRINOLYSIS; HOMEOSTASIS; HOMOZYGOTE; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOLECULAR CLONING; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; RETINA NEOVASCULARIZATION; VASCULAR RING; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; AORTA; CELL CULTURE; CELL MOTION; GENETICS; KINETICS; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANNEXIN A2; AORTA; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; ENDOTHELIUM, VASCULAR; FIBRIN; HOMEOSTASIS; KINETICS; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1542466792     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI19684     Document Type: Article

References (66)

1. Cines, D.B., et al. 1998. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 91:3527-3561.
2. Hajjar, K.A., Esmon, N.L., Marcus, A.J., and Muller, W.A. 2001. Vascular function in hemostasis. In Williams Hematology. E. Beuder, M.A. Lichtman, B.S. Coller, T.J. Kipps, and U. Seligsohn, editors. McGraw-Hill. New York, New York, USA, 1451-1469.
3. Jalbert, L.R., et al. 1998. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J. Clin. Invest. 102:1481-1488
4. Enjyoji, K., et al. 1999. Targeted disruption of CD39/ATP diphosphohy drolase results in disordered hemostasis and thromboregulation. Nat. Med. 5:1010-1017.
5. Semeraro, N., and Colucci, M. 1997. Tissue factor in health and disease. Thromb. Haemost. 78:759-764.
6. Hajjar, K.A. 2000. Molecular mechanisms of fibrolysis. In Williams hematology. E. Beuder, M.A Lichtman, B.S. Coller, T.J. Kipps, and U. Seligsohn, editors. McGraw-Hill. New York, New York, USA. 1479-1493.
7. Hajjar, K.A. 1998. The molecular basis of fibrinolysis. In Hematology of infancy and childhood. D.G. Nathan, and Orkin, S.H., editors. W.B. Saunders Co. Philadelphia, Pennsylvania, USA. 1557-1573.
8. Levin, EG., and del Zoppo, G.J. 1994. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am. J. Pathol. 144:855-861.
9. Levin, E.G., Santell, L., and Osborn, K.G. 1997. The expression of endothelial tissue plasminogen activator in vivo: a function defined by vessel size and anatomic location. J. Cell Sci. 110:139-148.
10. Rosenberg, R.D., and Aird, W.C. 1999. Vascular-bed-specific hemostasis and hypercoagulable states. N. Engl. J. Med. 340:1555-1564.
11. Bugge, T.H., Flick, M.J., Daugherty, C.C., and Degen, J.L. 1995. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9:794-807.
12. Ploplis, V.A., et al. 1995. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 92:2585-2593.
13. Carmeliet, P., et al. 1994. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 368:419-424.
14. Drew, A.F., et al. 1998. Ligneous conjunctivitis in plasminogen-deficient mice. Blood. 91:1616-1624.
15. Schott, D., et al. 1998. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N. Engl. J. Med. 339:1679-1686.
16. Hajjar, K.A., Jacovina, A.T., and Chacko, J. 1994. An endothelial cell receptor for plasminogen and tissue plasminogen activator: I. Identity with annexin II. J. Biol. Chem. 269:21191-21197.
17. Cesarman, G.M., Guevara, C.A., and Hajjar, K.A. 1994. An endothelial cell receptor for plasminogen/tissue plasminogen activator: II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biol. Chem. 269:21198-21203.
18. Ishii, H., et al. 2001. Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ. Res. 89:1240-1245.
19. Menell, J.S., et al. 1999. Annexin II and bleeding in acute promyelocytic leukemia. N. Engl. J. Med. 340:994-1004.
20. Nagashima, M., et al. 2002. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J. Clin. Invest. 109:101-110.
21. Konstantinides, S., Schafer, K., Koschnick, S., and Loskutoff, D.J. 2001. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J. Clin. Invest. 108:1533-1540.
22. Lodge, P.A., Haisch, C.E., and Thomas, F.T. 1992. A simple method of vascular endothelial cell isolation. Transplant. Proc. 24:2816-2817.
23. Jacovina, A.T., et al. 2001. Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation. J. Biol. Chem. 276:49350-49358.
24. Hiraoka, N., Allen, E., Apel, I.J., Gyetko, M.R., and Weiss, S.J. 1998. Matrix metalloproreinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95:365-377.
25. Devy, L., et al. 2002. The pro- or antiangiogenic effect of plasminogen activator inhibitor I is dose dependent. FASEB J. 16:147-154.
26. Weiler-Guettler, H., et al. 1998. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J. Clin. Invest. 101:1983-1991.
27. Christie, P.D., et al. 1999. A murine model of myocardial microvascular thrombosis. J. Clin. Invest. 104:533-539.
28. Passaniti, A., et al. 1992. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67:519-528.
29. Kenyon, B.M., et al. 1996. A model of angiogenesis in the mouse cornea Invest. Ophthalmol. Vis. Sci. 37:1625-1632.
30. Kenyon, B.M., Browne, F., and D'Amato, R.J. 1997. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64:971-978.
31. Smith, L.E.H., et al. 1994. Oxygen induced retinopathy in the mouse. Invest Ophthalmol. Vis. Sci. 35:101-111.
32. Ramos-DeSimone, N., et al. 1999. Activation of matrix metalloproteinase 9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274:13066-13076.
33. Netzel-Arnerr, S., et al. 2002. Collagen dissolution by kerarinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J. Biol. Chem. 277:45154-45161.
34. Hajjar, K.A., et al. 1998. Tissue plasminogen activator binding to the annexin II tail domain: direct modulation by homocysteine. J. Biol. Chem. 273:9987-9993.
35. Roldan, A.L., et al. 1990. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin-dependent proteolysis. EMBO J. 9:467-474.
36. Bugge, T.H., et al. 1995. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 270:16886-16894.
37. Dewerchin, M., et al. 1996. Generation and characterization of urokinase reeeptor-deficient mice. J. Clin. Invest. 97:870-878.
38. Wei, Y., Eble, J.A., Wang, Z., Kreidberg, J.A., and Chapman, H.A. 2001. Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol. Biol. Cell 12:2975-2986.
39. Simon, D.I., et al. 2000. Identification of a urokinase receptor-integrin interaction site: promiscuous regulator of integrin function. J. Biol. Chem. 275:10228-10234.
40. Schafer, K., et al. 2002. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circulation. 106:1847-1852.
41. Loskutoff, D.J., and Quigley, J.P. 2000. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J. Clin. Invest. 106:1441-1443.
42. Itoh, T., et al. 1997. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58:1048-1051.
43. Holmbeck, K., et al. 1999. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99:82-92.
44. Zhou, Z., et al. 2000. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type metalloproteinase. Proc. Natl. Acad. Sci. U. S. A. 97:4052-4057.
45. Vu, T., et al. 1998 MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93:411-422.
46. Kao, W.W.Y., et al. 1998. Healing of corneal epithelial defects in plasminogen- and fibrinogen-deficient mice. Invest. Ophthalmol. Vis. Sci. 39:502-508.
47. Drew, A.F., et al. 2000. Persistent corneal haze after excimer laser photokeratectomy in plasminogen-deficient mice. Invest. Ophthalmol. Vis. Sci. 41:67-72.
48. Leung, E.W., Rife, L., Smith, R.E., and Kay, E.P. 2000. Extracellular matrix components in retrocorneal fibrous membrane in comparison to corneal endothelium and Descemet's membrane. Mol. Vision. 6:15-23.
49. Hirsch, M., Prenant, G., and Renard, G. 2001. Three-dimensional supramolecular organization of the extracellular matrix in human and rabbit corneal stroma, as revealed by ultrarapid-freezing and deep-erching methods. Exp. Eye Res. 72:123-135.
50. Pierce, E.A., Avery, R.L., Foley, E.D., Aiello, L.P., and Smith, L.E.H. 1995. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. U. S. A. 92:905-909.
51. Ozaki, H., et al. 2000. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156:697-707.
52. Robinson, G.S., et al. 1996 Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. U. S. A. 93:4851-4856.
53. Aiello, L.M., et al. 1993. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using solu ble VEGF-recepror chimeric proteins. Proc. Natl. Acad. Sci. U. S. A. 921:10457-10461.
54. Heegaard, S., Jensen, O.A., and Prause, J.U. 1986. Structure and composition of the inner limiting membrane of the retina. Graefe's Arch. Clin. Exp. Ophthalmol. 224:355-360.
55. Browder, T., Folkman, J., and Pirie-Shepherd, S. 2000. The hemostatic system as a regulator of angiogenesis. J. Biol. Chem. 275:1521-1524.
56. Falcone, D.J., McCaffrey, T.A., Haimovitz-Friedman, A., Vergilio, J.A., and Nicholson, A.C. 1993. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J. Biol. Chem. 268:11951-11958.
57. Lyons, R.M., Gentry, L.E., Purchio, A.F., and Moses, H.L. 1990. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J. Cell Biol. 110:1361-1367.
58. Sporn, M.B., Roberts, A.B., Wakefield, L.M., and Assoian, R.K. 1986. Transforming growth factor-β: Biological function and chemical structure. Science 233:532-534.
59. Thiagarajan, P., Rappon, A.J., and Farrell, D.H. 1996. Alternative adhesion sites in human fibrinogen for vascular endothelial cells. Biochemistry. 35:4169-4175.
60. Thompson, W.D., et al. 1992. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J. Pathol. 168:47-53.
61. Chen, Z.L., and Strickland, S.E. 1997. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 91:917-925.
62. Werb, Z., Banda, P.A., and Jones, P.A. 1980. Degradation of connective tissue matrices by macrophages: I. Proteolysis of elastin, glycoproteins and collagen by proteinases isolated from macrophages. J. Exp. Med. 152:1340-1357.
63. Bach, T.L., Barsigian, C., Yaen, C.H., and Martinez, J. 1998. Endothelial cell VE-cadherin functions as a receptor for the β15-42 sequence of fibrin. J. Biol. Chem. 273:30719-30728.
64. Bach, T.L., et al. 1998. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp. Cell Res. 238:324-334.
65. Pendurthi, U.R., Ngyuen, M., Andrade-Gordon, P., Petersen, L.C., and Rao, L.V.M. 2002. Plasmin induces Cyr61 gene expression in fibroblasts via protesse activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signalling pathway. Arterioscler. Thromb. Vasc. Biol. 22:1421-1426.
66. Tarui, T., Majumdar, M., Miles, L.A., Ruf, W., and Takada, Y. 2002. Plasmin induced migration of endothelial cells. J. Biol. Chem. 277:33564-33570.